Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMRX Immuneering	$4.44 +0.7%	$5.03	$2.29 ▼ $10.08	$285.32M	0.38	1.95 million shs	1.07 million shs
RNAC Cartesian Therapeutics	$9.95 +3.3%	$7.34	$5.60 ▼ $15.57	$282.94M	0.66	446,185 shs	327,576 shs
SRZN Surrozen	$23.66 +1.8%	$27.47	$8.00 ▼ $35.00	$269.94M	0.51	109,030 shs	87,259 shs
UPXI Upexi	$0.87 -4.7%	$1.22	$0.54 ▼ $10.62	$63.77M	-0.35	2.36 million shs	3.83 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMRX Immuneering	+0.68%	+5.97%	-17.63%	-15.11%	+73.44%
RNAC Cartesian Therapeutics	+3.32%	+15.70%	+47.41%	+63.92%	+1.95%
SRZN Surrozen	+1.76%	+2.25%	-10.28%	-5.36%	+136.84%
UPXI Upexi	-4.69%	-19.91%	-35.45%	-22.07%	-90.65%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMRX Immuneering	$4.44 +0.7%	$5.03	$2.29 ▼ $10.08	$285.32M	0.38	1.95 million shs	1.07 million shs
RNAC Cartesian Therapeutics	$9.95 +3.3%	$7.34	$5.60 ▼ $15.57	$282.94M	0.66	446,185 shs	327,576 shs
SRZN Surrozen	$23.66 +1.8%	$27.47	$8.00 ▼ $35.00	$269.94M	0.51	109,030 shs	87,259 shs
UPXI Upexi	$0.87 -4.7%	$1.22	$0.54 ▼ $10.62	$63.77M	-0.35	2.36 million shs	3.83 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMRX Immuneering	+0.68%	+5.97%	-17.63%	-15.11%	+73.44%
RNAC Cartesian Therapeutics	+3.32%	+15.70%	+47.41%	+63.92%	+1.95%
SRZN Surrozen	+1.76%	+2.25%	-10.28%	-5.36%	+136.84%
UPXI Upexi	-4.69%	-19.91%	-35.45%	-22.07%	-90.65%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMRX Immuneering	2.83	Moderate Buy	$16.50	271.62% Upside
RNAC Cartesian Therapeutics	2.67	Moderate Buy	$32.60	227.64% Upside
SRZN Surrozen	2.80	Moderate Buy	$42.00	77.51% Upside
UPXI Upexi	2.67	Moderate Buy	$8.33	863.39% Upside

Current Analyst Ratings Breakdown

Latest UPXI, RNAC, IMRX, and SRZN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2026	RNAC Cartesian Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/10/2026	RNAC Cartesian Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$38.00
6/9/2026	RNAC Cartesian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
6/9/2026	RNAC Cartesian Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$44.00
6/8/2026	UPXI Upexi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/1/2026	IMRX Immuneering	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
5/27/2026	RNAC Cartesian Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$38.00
5/26/2026	RNAC Cartesian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$42.00 ➝ $40.00
5/22/2026	UPXI Upexi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/19/2026	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
5/12/2026	RNAC Cartesian Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$30.00 ➝ $25.00

(Data available from 6/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMRX Immuneering	N/A	N/A	N/A	N/A	$3.38 per share	N/A
RNAC Cartesian Therapeutics	$2.80M	104.40	N/A	N/A	($4.85) per share	-2.05
SRZN Surrozen	$3.48M	78.93	N/A	N/A	($19.21) per share	-1.23
UPXI Upexi	$15.81M	3.84	N/A	N/A	$1.01 per share	0.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMRX Immuneering	-$56.03M	-$1.17	N/A	N/A	N/A	N/A	-31.93%	-29.92%	8/12/2026 (Estimated)
RNAC Cartesian Therapeutics	-$130.30M	-$5.90	N/A	N/A	N/A	-8,550.65%	N/A	-28.25%	8/6/2026 (Estimated)
SRZN Surrozen	-$242.03M	-$37.59	N/A	N/A	N/A	-4,810.50%	-4,055.04%	-154.08%	8/14/2026 (Estimated)
UPXI Upexi	-$13.68M	-$0.62	N/A	N/A	N/A	-874.00%	-66.70%	-19.56%	9/2/2026 (Estimated)

Latest UPXI, RNAC, IMRX, and SRZN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2026	Q1 2026	IMRX Immuneering	-$0.30	-$0.21	+$0.09	-$0.21	N/A	N/A
5/12/2026	Q3 2026	UPXI Upexi	-$0.20	-$1.67	-$1.47	-$1.67	$2.90 million	$1.05 million
5/6/2026	Q1 2026	SRZN Surrozen	-$1.0920	-$11.65	-$10.5580	-$11.65	$4.00 million	$5.00 million
4/30/2026	Q1 2026	RNAC Cartesian Therapeutics	-$0.84	-$1.46	-$0.62	-$1.46	$0.22 million	$0.08 million
3/23/2026	Q4 2025	SRZN Surrozen	-$1.2875	-$7.59	-$6.3025	-$23.88	$0.66 million	$0.53 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMRX Immuneering	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A
UPXI Upexi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMRX Immuneering	N/A	32.45	32.45
RNAC Cartesian Therapeutics	N/A	7.65	7.65
SRZN Surrozen	N/A	11.91	11.91
UPXI Upexi	2.96	1.72	1.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMRX Immuneering	67.65%
RNAC Cartesian Therapeutics	86.95%
SRZN Surrozen	66.57%
UPXI Upexi	5.68%

Insider Ownership

Company	Insider Ownership
IMRX Immuneering	22.90%
RNAC Cartesian Therapeutics	37.20%
SRZN Surrozen	31.74%
UPXI Upexi	9.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMRX Immuneering	60	64.70 million	49.88 million	Not Optionable
RNAC Cartesian Therapeutics	64	29.38 million	18.45 million	Optionable
SRZN Surrozen	80	11.61 million	7.93 million	Not Optionable
UPXI Upexi	130	70.26 million	63.94 million	Optionable

UPXI, RNAC, IMRX, and SRZN Headlines

Recent News About These Companies

Upexi, Inc. Announces Pricing of ~$19.5 Million Private Placement of Common Stock

June 22 at 8:00 AM | globenewswire.com

Upexi (NASDAQ:UPXI) Trading Down 2.4% - Should You Sell?

June 18, 2026 | americanbankingnews.com

Upexi Shareholders Reelect Board and Ratify Auditor

June 16, 2026 | tipranks.com

UPXI Share News Today

May 19, 2026 | uk.investing.com

Upexi (UPXI) Stock Forecast & Price Target

May 15, 2026 | investing.com

Upexi Stock Short Interest Report | NASDAQ:UPXI | Benzinga

May 15, 2026 | benzinga.com

Upexi (UPXI) Q3 2026 Earnings Transcript

May 15, 2026 | fool.com

Upexi, Inc. Earnings Call Highlights Crypto-Fueled Volatility

May 13, 2026 | tipranks.com

Upexi Net Loss Balloons to $109 Million on Solana Treasury Markdown

May 13, 2026 | finance.yahoo.com

Upexi Reports Fiscal Third Quarter 2026 Financial Results

May 12, 2026 | globenewswire.com

Upexi Q3 2026 earnings preview

May 11, 2026 | msn.com

Upexi to Present at the LD Micro Invitational XVI Conference on May 17-19

May 7, 2026 | globenewswire.com

Upexi Provides Periodic Update to its Share Repurchase Program

May 6, 2026 | globenewswire.com

Upexi to Host Third Quarter 2026 Earnings Call on May 12th at 5:30 p.m. ET

May 5, 2026 | globenewswire.com

Upexi to Participate in the Scottsdale Capital Event on April 10-12

March 31, 2026 | globenewswire.com

Upexi to Participate in Upcoming March Investor Conferences

March 3, 2026 | globenewswire.com

Upexi Earnings Call: Growth Surges, Losses Mount

February 15, 2026 | tipranks.com

Insiders' US$4.22m Investments In Red Following Upexi's US$18m Dip In Market Value

February 14, 2026 | finance.yahoo.com

Upexi Inc (UPXI) Q2 2026 Earnings Call Highlights: Revenue Soars Amid Digital Asset Challenges

February 13, 2026 | uk.finance.yahoo.com

Upexi Inc (UPXI) Q2 2026 Earnings Call Highlights: Revenue Soars Amid Digital Asset Challenges

February 13, 2026 | uk.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPXI, RNAC, IMRX, and SRZN Company Descriptions

Immuneering NASDAQ:IMRX

$4.44 +0.03 (+0.68%)

Closing price 06/22/2026 04:00 PM Eastern

Extended Trading

$4.42 -0.02 (-0.34%)

As of 06/22/2026 07:57 PM Eastern

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Cartesian Therapeutics NASDAQ:RNAC

$9.95 +0.32 (+3.32%)

Closing price 06/22/2026 04:00 PM Eastern

Extended Trading

$9.72 -0.23 (-2.26%)

As of 06/22/2026 07:08 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Surrozen NASDAQ:SRZN

$23.66 +0.41 (+1.76%)

Closing price 06/22/2026 04:00 PM Eastern

Extended Trading

$23.64 -0.02 (-0.06%)

As of 06/22/2026 04:10 PM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

Upexi NASDAQ:UPXI

$0.86 -0.04 (-4.69%)

Closing price 06/22/2026 04:00 PM Eastern

Extended Trading

$0.88 +0.01 (+1.62%)

As of 06/22/2026 07:59 PM Eastern

Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UPXI, RNAC, IMRX, and SRZN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UPXI, RNAC, IMRX, and SRZN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UPXI, RNAC, IMRX, and SRZN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPXI, RNAC, IMRX, and SRZN Company Descriptions

Immuneering NASDAQ:IMRX

Cartesian Therapeutics NASDAQ:RNAC

Surrozen NASDAQ:SRZN

Upexi NASDAQ:UPXI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UPXI, RNAC, IMRX, and SRZN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UPXI, RNAC, IMRX, and SRZN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UPXI, RNAC, IMRX, and SRZN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPXI, RNAC, IMRX, and SRZN Company Descriptions

Immuneering NASDAQ:IMRX

Cartesian Therapeutics NASDAQ:RNAC

Surrozen NASDAQ:SRZN

Upexi NASDAQ:UPXI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools